ArticleJournal of translational medicine2026
Protection of GAP-43 gene-modified bone marrow mesenchymal stem cells on retinitis pigmentosa.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundTo observe the therapeutic effects of growth associated protein-43 (GAP 43) gene modified rat bone marrow mesenchymal stem cells (BMSCs) on experimental retinal degeneration.
methodsA total of 80 male Royal College of Surgeons (RCS) rats were divided into three groups at postnatal 21 (P21) randomly. A cell suspension of 5 × 104 BMSCs modified with GAP-43 in 2 µl PBS was injected into the subretinal space of BMSCs + GAP-43 group rats, BMSCs group rats received5 × 104 BMSCs in 2 µl PBS and PBS group rats received 2 µl PBS. Photoreceptor necrosis and apoptosis was assessed by HE staining and Terminal-deoxynucleotidyl Transferase Mediated Nick End Labeling (TUNEL) detection. The expression of GAP-43, Glutamine synthetase (GS), rhodopsin (RHO), Caspase-8 and Caspase-9 was analyzed by immunofluorescence, western blot.
resultsTransplantation of GAP-43-modified BMSCs into the subretinal cavity of RCS rats revealed that: retinal GAP-43 expression was significantly elevated (P < 0.05); Rhodopsin (Rho) expression, a photoreceptor marker, was upregulated 1.5-fold (P < 0.05), and the thickness of the outer nuclear layer increased to 79.78 ± 6.83 μm (control 29.92 ± 4.17 μm, P < 0.01); The apoptosis rate decreased to 41.9% (control 63.8%, P < 0.01), and Caspase-8/9 activation was inhibited; Müller cell proliferation was reduced (GS decreased, P < 0.05). suggesting that GAP-43-modified BMSCs delayed retinal degeneration through anti-apoptosis and pro-photoreceptor survival.
conclusionsThe results suggest that GAP-43 gene modified BMSCs has the therapeutic effect on the early stage of retinal degeneration, which might make more photoreceptors preserved.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.